ChemSpider 2D Image | GSK1292263 | C23H28N4O4S

GSK1292263

  • Molecular FormulaC23H28N4O4S
  • Average mass456.558 Da
  • Monoisotopic mass456.183136 Da
  • ChemSpider ID25027409

More details:

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

1032823-75-8 [RN]
2-(4-methanesulfonylphenyl)-5-({1-[3-(propan-2-yl)-1,2,4-oxadiazol-5-yl]piperidin-4-yl}methoxy)pyridine
5-{[1-(3-Isopropyl-1,2,4-oxadiazol-5-yl)-4-piperidinyl]methoxy}-2-[4-(methylsulfonyl)phenyl]pyridin [German] [ACD/IUPAC Name]
5-{[1-(3-Isopropyl-1,2,4-oxadiazol-5-yl)-4-piperidinyl]methoxy}-2-[4-(methylsulfonyl)phenyl]pyridine [ACD/IUPAC Name]
5-{[1-(3-Isopropyl-1,2,4-oxadiazol-5-yl)-4-pipéridinyl]méthoxy}-2-[4-(méthylsulfonyl)phényl]pyridine [French] [ACD/IUPAC Name]
5-{[1-(3-ISOPROPYL-1,2,4-OXADIAZOL-5-YL)PIPERIDIN-4-YL]METHOXY}-2-(4-METHANESULFONYLPHENYL)PYRIDINE
GSK1292263
GSK-1292263
Pyridine, 5-[[1-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-4-piperidinyl]methoxy]-2-[4-(methylsulfonyl)phenyl]- [ACD/Index Name]
[1032823-75-8] [RN]
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

R1J57STA6O [DBID]
UNII:R1J57STA6O [DBID]
UNII-R1J57STA6O [DBID]
  • Experimental Physico-chemical Properties
  • Miscellaneous

    • Target Organs:

      GPR Agonist TargetMol T2701

    • Bio Activity:

      Endocrinology/ Hormones TargetMol T2701
      GPCR/G protein MedChem Express HY-12066
      GPCR/G protein; MedChem Express HY-12066
      GPR119 MedChem Express HY-12066
      GPR119 TargetMol T2701
      GSK1292263 is a novel GPR119 receptor agonist used for the treatment of type 2 diabetes. MedChem Express
      GSK1292263 is a novel GPR119 receptor agonist used for the treatment of type 2 diabetes.; IC50 value:; Target: GPR119; in vitro: GSK-1292263 is selected from 1538 compounds by using Hypo1, the Fit-Value and Estimate of GSK-1292263 that is aligned in Hypo1 are 8.8 and 7.7 (nM), respectively [1]. MedChem Express HY-12066
      GSK1292263 is a novel GPR119 receptor agonist used for the treatment of type 2 diabetes.;IC50 value:;Target: GPR119;In vitro: GSK-1292263 is selected from 1538 compounds by using Hypo1, the Fit-Value and Estimate of GSK-1292263 that is aligned in Hypo1 are 8.8 and 7.7 (nM), respectively [1]. ;In vivo: GSK-1292263 administrated at a single dose of 3-30 mg/kg in the absence of nutrients correlates with increased levels of circulating gastrointestinal peptides, including glucagon-like peptide 1 (GLP-1), gastric inhibitory polypeptide (GIP), peptide YY (PYY) and glucagon in male Sprague-Dawley rats, the increase is enhanced following administration of glucose in the oral glucose tolerance test (OGTT). GSK-129226 significant increases in the peak insulin response and insulin AUC(0-15 min) of 30-60% compared with values in the vehicle control cohort in the intravenous glucose tolerance test in rats, this insulin upregulation correlated with a significant increase in the glucose disposal MedChem Express HY-12066

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module, version: 14.00

Density: 1.2±0.1 g/cm3
Boiling Point: 655.1±65.0 °C at 760 mmHg
Vapour Pressure: 0.0±2.0 mmHg at 25°C
Enthalpy of Vaporization: 96.5±3.0 kJ/mol
Flash Point: 350.0±34.3 °C
Index of Refraction: 1.565
Molar Refractivity: 120.7±0.4 cm3
#H bond acceptors: 8
#H bond donors: 0
#Freely Rotating Bonds: 7
#Rule of 5 Violations: 0
ACD/LogP: 1.67
ACD/LogD (pH 5.5): 2.01
ACD/BCF (pH 5.5): 18.29
ACD/KOC (pH 5.5): 252.80
ACD/LogD (pH 7.4): 2.16
ACD/BCF (pH 7.4): 25.67
ACD/KOC (pH 7.4): 354.68
Polar Surface Area: 107 Å2
Polarizability: 47.8±0.5 10-24cm3
Surface Tension: 49.1±3.0 dyne/cm
Molar Volume: 370.8±3.0 cm3

Click to predict properties on the Chemicalize site


Advertisement